Selectivity of commonly used pharmacological inhibitors for cystathionine β synthase (CBS) and cystathionine γ lyase (CSE)

British Journal of Pharmacology

Volumn 169, Issue 4, 2013, Pages 922-932

  Asimakopoulou, Antonia ^a   Panopoulos, Panagiotis ^a   Chasapis, Christos T ^a   Coletta, Ciro ^b   Zhou, Zongmin ^c   Cirino, Giuseppe ^d   Giannis, Athanassios ^e   Szabo, Csaba ^b   Spyroulias, Georgios A ^a   Papapetropoulos, Andreas ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

cyano L alanine; aminooxyacetic acid; cystathionine synthase; cystathionine lyase; DL propargylglycine; hydrogen sulfide; nitric oxide; pyridoxal 5 phosphate

Indexed keywords

AMINOETHOXYVINYLGLYCINE; AMINOOXYACETIC ACID; CYANOALANINE; CYSTATHIONINE BETA SYNTHASE INHIBITOR; CYSTATHIONINE GAMMA LYASE INHIBITOR; CYSTEINE; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; HYDROGEN SULFIDE; HYDROXYLAMINE; LYASE INHIBITOR; METHYLENE BLUE; NITRIC OXIDE; PROPARGYLGLYCINE; TRIFLUOROALANINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME PURIFICATION; ESCHERICHIA COLI; HUMAN; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASCULAR RING;

ALANINE; ALKYNES; ANIMALS; AORTA, THORACIC; CYSTATHIONINE BETA-SYNTHASE; CYSTATHIONINE GAMMA-LYASE; ENZYME INHIBITORS; GLUTATHIONE TRANSFERASE; GLYCINE; HUMANS; HYDROGEN SULFIDE; KINETICS; NITRIC OXIDE; NITRIC OXIDE DONORS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; VASODILATION;

EID: 84878275590     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12171     Document Type: Article

References (50)

1. Alston TA, Porter DJ, Mela L, Bright HJ, (1980). Inactivation of alanine aminotransferase by the neurotoxin beta-cyano-L-alanine. Biochem Biophys Res Commun 92: 299-304.
2. Bianchetti A, Lavezzo A, Carminati P, (1982). The non-steroidal anti-inflammatory agent parsalmide prevents aspirin-induced H+ back diffusion from the gastric lumen of the rat. J Pharm Pharmacol 34: 51-53.
3. Bucci M, Mirone V, Di Lorenzo A, Vellecco V, Roviezzo F, Brancaleone V, et al. (2009). Hydrogen sulphide is involved in testosterone vascular effect. Eur Urol 56: 378-383.
4. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Pyriochou A, Roussos C, et al. (2010). Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arterioscler Thromb Vasc Biol 30: 1998-2004.
5. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH, (1992). Nitric oxide: a physiologic mediator of penile erection. Science 257: 401-403.
6. Chiku T, Padovani D, Zhu W, Singh S, Vitvitsky V, Banerjee R, (2009). H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia. J Biol Chem 284: 11601-11612.
7. Clausen T, Huber R, Messerschmidt A, Pohlenz HD, Laber B, (1997). Slow-binding inhibition of Escherichia coli cystathionine beta-lyase by L-aminoethoxyvinylglycine: a kinetic and X-ray study. Biochemistry 36: 12633-12643.
8. Clausen T, Huber R, Prade L, Wahl MC, Messerschmidt A, (1998). Crystal structure of Escherichia coli cystathionine gamma-synthase at 1.5 A resolution. EMBO J 17: 6827-6838.
9. Cornell NW, Zuurendonk PF, Kerich MJ, Straight CB, (1984). Selective inhibition of alanine aminotransferase and aspartate aminotransferase in rat hepatocytes. Biochem J 220: 707-716.
10. DeMaster EG, Raij L, Archer SL, Weir EK, (1989). Hydroxylamine is a vasorelaxant and a possible intermediate in the oxidative conversion of L-arginine to nitric oxide. Biochem Biophys Res Commun 163: 527-533.
11. d'Emmanuele di Villa Bianca R, Sorrentino R, Maffia P, Mirone V, Imbimbo C, Fusco F, et al. (2009). Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle relaxation. Proc Natl Acad Sci U S A 106: 4513-4518.
12. Eto K, Kimura H, (2002). A novel enhancing mechanism for hydrogen sulfide-producing activity of cystathionine beta-synthase. J Biol Chem 277: 42680-42685.
13. Evande R, Ojha S, Banerjee R, (2004). Visualization of PLP-bound intermediates in hemeless variants of human cystathionine beta-synthase: evidence that lysine 119 is a general base. Arch Biochem Biophys 427: 188-196.
14. Frank N, Kent JO, Meier M, Kraus JP, (2008). Purification and characterization of the wild type and truncated human cystathionine beta-synthase enzymes expressed in E. coli. Arch Biochem Biophys 470: 64-72.
15. Goldberg LI, (1964). Monoamine oxidase inhibitors. Adverse reactions and possible mechanisms. JAMA 190: 456-462.
16. Gross P, (1985). Biologic activity of hydroxylamine: a review. Crit Rev Toxicol 14: 87-99.
17. Huang S, Chua JH, Yew WS, Sivaraman J, Moore PK, Tan CH, et al. (2009). Site-directed mutagenesis on human cystathionine-gamma-lyase reveals insights into the modulation of H2S production. J Mol Biol 396: 708-718.
18. Huang S, Chua JH, Yew WS, Sivaraman J, Moore PK, Tan CH, et al. (2010). Site-directed mutagenesis on human cystathionine-gamma-lyase reveals insights into the modulation of H2S production. J Mol Biol 396: 708-718.
19. Kabil O, Banerjee R, (2010). Redox biochemistry of hydrogen sulfide. J Biol Chem 285: 21903-21907.
20. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
21. Kimura H, (2010). Hydrogen sulfide: from brain to gut. Antioxid Redox Signal 12: 1111-1123.
22. Konno R, Ikeda M, Yamaguchi K, Ueda Y, Niwa A, (2000). Nephrotoxicity of d-propargylglycine in mice. Arch Toxicol 74: 473-479.
23. Lavu M, Bhushan S, Lefer DJ, (2010). Hydrogen sulfide-mediated cardioprotection: mechanisms and therapeutic potential. Clin Sci (Lond) 120: 219-229.
24. Li L, Rose P, Moore P, (2011). Hydrogen sulfide and cell signaling. Annu Rev Pharmacol Toxicol 51: 169-187.
25. Majtan T, Singh L, Wang L, Kruger W, Kraus J, (2008). Active cystathionine beta-synthase can be expressed in haem-free systems in the presence of metal-substituted porphyrins or a chemical chaperone. J Biol Chem 283: 34588-34595.
26. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
27. Mok YY, Atan MS, Yoke Ping C, Zhong Jing W, Bhatia M, Moochhala S, et al. (2004). Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect of inhibitors of hydrogen sulphide biosynthesis. Br J Pharmacol 143: 881-889.
28. Papapetropoulos A, Pyriochou A, Altaany Z, Yang G, Marazioti A, Zhou Z, et al. (2009). Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci U S A 106: 21972-21977.
29. Paul B, Snyder S, (2012). H2S signalling through protein sulfhydration and beyond. Nat Rev Mol Cell Biol 13: 499-507.
30. Pruess DL, Scannell JP, Kellett M, Ax HA, Janecek J, Williams TH, et al. (1974). Antimetabolites produced by microorganisms. X. L-2-amino-4-(2- aminoethoxy)-trans-3-butenoic acid. J Antibiot (Tokyo) 27: 229-233.
31. Rej R, (1977). Aminooxyacetate is not an adequate differential inhibitor of aspartate aminotransferase isoenzymes. Clin Chem 23: 1508-1509.
32. Ressler C, (1962). Isolation and identification from common vetch of the neurotoxin beta-cyano-L-alanine, a possible factor in neurolathyrism. J Biol Chem 237: 733-735.
33. Ressler C, Nelson J, Pfeffer M, (1964). A pyridoxal-beta-cyanoalanine relation in the rat. Nature 203: 1286-1287.
34. Riccardi G, Pasca MR, Buroni S, (2009). Mycobacterium tuberculosis: drug resistance and future perspectives. Future Microbiol 4: 597-614.
35. Roy A, Khan AH, Islam MT, Prieto MC, Majid DS, (2011). Interdependency of cystathione gamma-lyase and cystathione beta-synthase in hydrogen sulfide-induced blood pressure regulation in rats. Am J Hypertens 25: 74-81.
36. Silverman RB, Abeles RH, (1976). Inactivation of pyridoxal phosphate dependent enzymes by mono- and polyhaloalanines. Biochemistry 15: 4718-4723.
37. Silverman RB, Abeles RH, (1977). Mechanism of inactivation of gamma cystathionate by beta, beta, beta trifluoroalanine. Biochemistry 16: 5515-5520.
38. Singh S, Padovani D, Leslie RA, Chiku T, Banerjee R, (2009). Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions. J Biol Chem 284: 22457-22466.
39. Spooren AA, Evelo CT, (1997). Hydroxylamine treatment increases glutathione-protein and protein-protein binding in human erythrocytes. Blood Cells Mol Dis 23: 323-336.
40. Steegborn C, Clausen T, Sondermann P, Jacob U, Worbs M, Marinkovic S, et al. (1999). Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration. J Biol Chem 274: 12675-12684.
41. Stipanuk MH, Beck PW, (1982). Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. Biochem J 206: 267-277.
42. Sun Q, Collins R, Huang S, Holmberg-Schiavone L, Anand GS, Tan CH, et al. (2009). Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S. J Biol Chem 284: 3076-3085.
43. Szabo C, (2007). Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6: 917-935.
44. Tanase S, Morino Y, (1976). Irreversible inactivation of aspartate aminotransferases during transamination with L-propargylglycine. Biochem Biophys Res Commun 68: 1301-1308.
45. Tang G, Adu-Sarkodie K, Kim D, Kim JH, Teefy S, Shukairy HM, et al. (2005). Modeling Cryptosporidium parvum oocyst inactivation and bromate formation in a full-scale ozone contactor. Environ Sci Technol 39: 9343-9350.
46. Taoka S, Banerjee R, (2001). Characterization of NO binding to human cystathionine beta-synthase: possible implications of the effects of CO and NO binding to the human enzyme. J Inorg Biochem 87: 245-251.
47. Wang R, (2012). Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev 92: 791-896.
48. Whiteman M, Winyard PG, (2011). Hydrogen sulfide and inflammation: the good, the bad, the ugly and the promising. Expert Rev Clin Pharmacol 4: 13-32.
49. Whiteman M, Gooding KM, Whatmore JL, Ball CI, Mawson D, Skinner K, et al. (2010). Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia 53: 1722-1726.
50. Whiteman M, Le Trionnaire S, Chopra M, Fox B, Whatmore J, (2011). Emerging role of hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological tools. Clin Sci (Lond) 121: 459-488.